The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC).
{iframe}http://www.europeanpharmaceuticalreview.com/45125/news/industry-news/fda-assay-lung-cancer/{/iframe}